A new study will use innovative methods developed at VUMC to look for drugs already approved for other uses that could potentially be repurposed to treat Alzheimer's.

With stroke care evolving rapidly, the event aims to improve stroke care in Middle Tennessee and beyond through continuing medical education.

Orkin's research led to a gene therapy for sickle cell disease and beta-thalassemia; it is the first Food and Drug Administration-approved CRISPR-based gene therapy.

She served in a number of leadership roles, including evening hospital administrator and assistant hospital director for VUH. She was an administrative director for several areas, including LifeFlight and the Burn Patient Care Center, and helped guide the creation of VUH’s dedicated Trauma Intensive Care Unit.

Positive findings from a clinical trial support further study of the investigational drug ifetroban to treat cardiac complications, the leading cause of death in patients with DMD.

“Melissa Smith is the heart and soul of the trauma program and is involved in every aspect of the oversight and functioning of the trauma service.”

Former patients who recovered from serious illness and life-preserving surgeries in the SICU returned for a “Great Saves” event to share health updates and their gratitude with the people they credit with saving their lives.